BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ogawa T, Enomoto M, Fujii H, Sekiya Y, Yoshizato K, Ikeda K, Kawada N. MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis. Gut. 2012;61:1600-1609. [PMID: 22267590 DOI: 10.1136/gutjnl-2011-300717] [Cited by in Crossref: 159] [Cited by in F6Publishing: 150] [Article Influence: 15.9] [Reference Citation Analysis]
Number Citing Articles
1 Wang D, Sang Y, Sun T, Kong P, Zhang L, Dai Y, Cao Y, Tao Z, Liu W. Emerging roles and mechanisms of microRNA‑222‑3p in human cancer (Review). Int J Oncol 2021;58:20. [PMID: 33760107 DOI: 10.3892/ijo.2021.5200] [Reference Citation Analysis]
2 Zhao F. Dysregulated Epigenetic Modifications in the Pathogenesis of NAFLD-HCC. In: Yu J, editor. Obesity, Fatty Liver and Liver Cancer. Singapore: Springer; 2018. pp. 79-93. [DOI: 10.1007/978-981-10-8684-7_7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
3 Baffy G. MicroRNAs in Nonalcoholic Fatty Liver Disease. J Clin Med. 2015;4:1977-1988. [PMID: 26690233 DOI: 10.3390/jcm4121953] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 6.7] [Reference Citation Analysis]
4 Gu S, Cheung HH, Lee TL, Lu G, Poon WS, Chan WY. Molecular mechanisms of regulation and action of microRNA-199a in testicular germ cell tumor and glioblastomas. PLoS One 2013;8:e83980. [PMID: 24391856 DOI: 10.1371/journal.pone.0083980] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
5 Gabbia D, Carpi S, Sarcognato S, Cannella L, Colognesi M, Scaffidi M, Polini B, Digiacomo M, Esposito Salsano J, Manera C, Macchia M, Nieri P, Carrara M, Russo FP, Guido M, De Martin S. The Extra Virgin Olive Oil Polyphenol Oleocanthal Exerts Antifibrotic Effects in the Liver. Front Nutr 2021;8:715183. [PMID: 34671630 DOI: 10.3389/fnut.2021.715183] [Reference Citation Analysis]
6 Chen P, Li J, Huo Y, Lu J, Wan L, Li B, Gan R, Guo C. Orphan nuclear receptor NR4A2 inhibits hepatic stellate cell proliferation through MAPK pathway in liver fibrosis. PeerJ 2015;3:e1518. [PMID: 26713258 DOI: 10.7717/peerj.1518] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
7 Emma MR, Giannitrapani L, Cabibi D, Porcasi R, Pantuso G, Augello G, Giglio RV, Re NL, Capitano AR, Montalto G, Soresi M, Cervello M. Hepatic and circulating levels of PCSK9 in morbidly obese patients: Relation with severity of liver steatosis. Biochim Biophys Acta Mol Cell Biol Lipids 2020;1865:158792. [PMID: 32777481 DOI: 10.1016/j.bbalip.2020.158792] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Chen P, Li J, Huo Y, Lu J, Wan L, Yang Q, Huang J, Gan R, Guo C. Adenovirus-mediated expression of orphan nuclear receptor NR4A2 targeting hepatic stellate cell attenuates liver fibrosis in rats. Sci Rep 2016;6:33593. [PMID: 27646469 DOI: 10.1038/srep33593] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
9 Lee J, Kim Y, Friso S, Choi SW. Epigenetics in non-alcoholic fatty liver disease. Mol Aspects Med. 2016; Nov 23. [Epub ahead of print]. [PMID: 27889327 DOI: 10.1016/j.mam.2016.11.008] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 9.7] [Reference Citation Analysis]
10 Shi CX, Wang Y, Jiao FZ, Chen Q, Cao P, Pei MH, Zhang LY, Guo J, Deng W, Wang LW, Gong ZJ. Epigenetic Regulation of Hepatic Stellate Cell Activation and Macrophage in Chronic Liver Inflammation. Front Physiol 2021;12:683526. [PMID: 34276405 DOI: 10.3389/fphys.2021.683526] [Reference Citation Analysis]
11 You H, Wang L, Bu F, Meng H, Pan X, Li J, Zhang Y, Wang A, Yin N, Huang C, Li J. The miR-455-3p/HDAC2 axis plays a pivotal role in the progression and reversal of liver fibrosis and is regulated by epigenetics. FASEB J 2021;35:e21700. [PMID: 34105828 DOI: 10.1096/fj.202002319RRR] [Reference Citation Analysis]
12 Verjans R, Peters T, Beaumont FJ, van Leeuwen R, van Herwaarden T, Verhesen W, Munts C, Bijnen M, Henkens M, Diez J, de Windt LJ, van Nieuwenhoven FA, van Bilsen M, Goumans MJ, Heymans S, González A, Schroen B. MicroRNA-221/222 Family Counteracts Myocardial Fibrosis in Pressure Overload-Induced Heart Failure. Hypertension 2018;71:280-8. [PMID: 29255073 DOI: 10.1161/HYPERTENSIONAHA.117.10094] [Cited by in Crossref: 67] [Cited by in F6Publishing: 46] [Article Influence: 13.4] [Reference Citation Analysis]
13 Motawi TMK, Sadik NAH, Shaker OG, Ghaleb MH. Elevated serum microRNA-122/222 levels are potential diagnostic biomarkers in Egyptian patients with chronic hepatitis C but not hepatic cancer. Tumor Biol 2016;37:9865-74. [DOI: 10.1007/s13277-016-4884-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
14 Dong R, Zheng Y, Chen G, Zhao R, Zhou Z, Zheng S. miR-222 Overexpression May Contribute to Liver Fibrosis in Biliary Atresia by Targeting PPP2R2A. Journal of Pediatric Gastroenterology & Nutrition 2015;60:84-90. [DOI: 10.1097/mpg.0000000000000573] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
15 Guo CJ, Pan Q, Xiong H, Qiao YQ, Bian ZL, Zhong W, Sheng L, Li H, Shen L, Hua J, Ma X. Therapeutic potential of microRNA: a new target to treat intrahepatic portal hypertension? Biomed Res Int 2014;2014:797898. [PMID: 24812632 DOI: 10.1155/2014/797898] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
16 Shen WJ, Dong R, Chen G, Zheng S. microRNA-222 modulates liver fibrosis in a murine model of biliary atresia. Biochem Biophys Res Commun. 2014;446:155-159. [PMID: 24569080 DOI: 10.1016/j.bbrc.2014.02.065] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
17 Deng J, Huang Y, Tao R, Fan X, Zhang H, Kong H, Song Q, Huang J. The expression of ETAR in liver cirrhosis and liver cancer. Cancer Biol Ther 2017;18:723-9. [PMID: 28812426 DOI: 10.1080/15384047.2017.1360451] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
18 Iizuka M, Ogawa T, Enomoto M, Motoyama H, Yoshizato K, Ikeda K, Kawada N. Induction of microRNA-214-5p in human and rodent liver fibrosis. Fibrogenesis Tissue Repair. 2012;5:12. [PMID: 22849305 DOI: 10.1186/1755-1536-5-12] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 5.8] [Reference Citation Analysis]
19 Kulkarni SR, Armstrong LE, Slitt AL. Caloric restriction-mediated induction of lipid metabolism gene expression in liver is enhanced by Keap1-knockdown. Pharm Res 2013;30:2221-31. [PMID: 23884569 DOI: 10.1007/s11095-013-1138-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
20 Zhu J, Zhang Z, Zhang Y, Li W, Zheng W, Yu J, Wang B, Chen L, Zhuo Q, Chen L, Zhang J, Liu J. MicroRNA-212 activates hepatic stellate cells and promotes liver fibrosis via targeting SMAD7. Biochem Biophys Res Commun 2018;496:176-83. [PMID: 29307832 DOI: 10.1016/j.bbrc.2018.01.019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
21 Marsh EE, Steinberg ML, Parker JB, Wu J, Chakravarti D, Bulun SE. Decreased expression of microRNA-29 family in leiomyoma contributes to increased major fibrillar collagen production. Fertil Steril 2016;106:766-72. [PMID: 27233758 DOI: 10.1016/j.fertnstert.2016.05.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
22 Lee YA, Wallace MC, Friedman SL. Pathobiology of liver fibrosis: a translational success story. Gut 2015;64:830-41. [PMID: 25681399 DOI: 10.1136/gutjnl-2014-306842] [Cited by in Crossref: 485] [Cited by in F6Publishing: 463] [Article Influence: 69.3] [Reference Citation Analysis]
23 Wang JJ, Zhang YT, Tseng YJ, Zhang J. miR-222 targets ACOX1, promotes triglyceride accumulation in hepatocytes. Hepatobiliary Pancreat Dis Int 2019;18:360-5. [PMID: 31126802 DOI: 10.1016/j.hbpd.2019.05.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
24 Mann J, Mann DA. Epigenetic regulation of wound healing and fibrosis. Current Opinion in Rheumatology 2013;25:101-7. [DOI: 10.1097/bor.0b013e32835b13e1] [Cited by in Crossref: 55] [Cited by in F6Publishing: 27] [Article Influence: 6.1] [Reference Citation Analysis]
25 Bayoumi A, Grønbæk H, George J, Eslam M. The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver Disease. Trends Genet 2020;36:429-41. [PMID: 32396836 DOI: 10.1016/j.tig.2020.03.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
26 Cabantous S, Hou X, Louis L, He H, Mariani O, Sastre X, Daujat-Chavanieu M, Li Y, Dessein A. Evidence for an important role of host microRNAs in regulating hepatic fibrosis in humans infected with Schistosoma japonicum. Int J Parasitol 2017;47:823-30. [PMID: 28739251 DOI: 10.1016/j.ijpara.2017.05.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
27 Bu FT, Zhu Y, Chen X, Wang A, Zhang YF, You HM, Yang Y, Yang YR, Huang C, Li J. Circular RNA circPSD3 alleviates hepatic fibrogenesis by regulating the miR-92b-3p/Smad7 axis. Mol Ther Nucleic Acids 2021;23:847-62. [PMID: 33614234 DOI: 10.1016/j.omtn.2021.01.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Bozaykut P, Sahin A, Karademir B, Ozer NK. Endoplasmic reticulum stress related molecular mechanisms in nonalcoholic steatohepatitis. Mechanisms of Ageing and Development 2016;157:17-29. [DOI: 10.1016/j.mad.2016.07.001] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 6.8] [Reference Citation Analysis]
29 Song J, Ouyang Y, Che J, Li X, Zhao Y, Yang K, Zhao X, Chen Y, Fan C, Yuan W. Potential Value of miR-221/222 as Diagnostic, Prognostic, and Therapeutic Biomarkers for Diseases. Front Immunol 2017;8:56. [PMID: 28261196 DOI: 10.3389/fimmu.2017.00056] [Cited by in Crossref: 57] [Cited by in F6Publishing: 66] [Article Influence: 11.4] [Reference Citation Analysis]
30 Dong Z, Li S, Wang X, Si L, Ma R, Bao L, Bo A. lncRNA GAS5 restrains CCl4-induced hepatic fibrosis by targeting miR-23a through the PTEN/PI3K/Akt signaling pathway. Am J Physiol Gastrointest Liver Physiol. 2019;316:G539-G550. [PMID: 30735452 DOI: 10.1152/ajpgi.00249.2018] [Cited by in Crossref: 23] [Cited by in F6Publishing: 29] [Article Influence: 7.7] [Reference Citation Analysis]
31 Lee CH, Kim JH, Lee SW. The role of microRNAs in hepatitis C virus replication and related liver diseases. J Microbiol. 2014;52:445-451. [PMID: 24871972 DOI: 10.1007/s12275-014-4267-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
32 Xu G, Yang F, Ding CL, Wang J, Zhao P, Wang W, Ren H. MiR-221 accentuates IFN׳s anti-HCV effect by downregulating SOCS1 and SOCS3. Virology 2014;462-463:343-50. [PMID: 25019494 DOI: 10.1016/j.virol.2014.06.024] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 6.8] [Reference Citation Analysis]
33 Zhang P, Yu J, Gui Y, Sun C, Han W. Inhibition of miRNA-222-3p Relieves Staphylococcal Enterotoxin B-Induced Liver Inflammatory Injury by Upregulating Suppressors of Cytokine Signaling 1. Yonsei Med J 2019;60:1093-102. [PMID: 31637892 DOI: 10.3349/ymj.2019.60.11.1093] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
34 Matsuzaki J, Suzuki H. Role of MicroRNAs-221/222 in Digestive Systems. J Clin Med 2015;4:1566-77. [PMID: 26258795 DOI: 10.3390/jcm4081566] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
35 Yang Y, Xing Y, Liang C, Hu L, Xu F, Mei Q. An examination of the regulatory mechanism of Pxdn mutation-induced eye disorders using microarray analysis. Int J Mol Med 2016;37:1449-56. [PMID: 27121343 DOI: 10.3892/ijmm.2016.2572] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
36 Halász T, Horváth G, Pár G, Werling K, Kiss A, Schaff Z, Lendvai G. miR-122 negatively correlates with liver fibrosis as detected by histology and FibroScan. World J Gastroenterol 2015; 21(25): 7814-7823 [PMID: 26167081 DOI: 10.3748/wjg.v21.i25.7814] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 34] [Article Influence: 5.1] [Reference Citation Analysis]
37 Cai P, Mu Y, Olveda RM, Ross AG, Olveda DU, McManus DP. Circulating miRNAs as footprints for liver fibrosis grading in schistosomiasis. EBioMedicine 2018;37:334-43. [PMID: 30482723 DOI: 10.1016/j.ebiom.2018.10.048] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
38 Waldron PR, Holodniy M. MicroRNA and hepatitis C virus--challenges in investigation and translation: a review of the literature. Diagn Microbiol Infect Dis 2014;80:1-12. [PMID: 24996839 DOI: 10.1016/j.diagmicrobio.2014.05.024] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
39 Lu L, Wang J, Lu H, Zhang G, Liu Y, Wang J, Zhang Y, Shang H, Ji H, Chen X, Duan Y, Li Y. MicroRNA-130a and -130b enhance activation of hepatic stellate cells by suppressing PPARγ expression: A rat fibrosis model study. Biochem Biophys Res Commun 2015;465:387-93. [PMID: 26255201 DOI: 10.1016/j.bbrc.2015.08.012] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
40 Littlejohn GO. Fibrositis/fibromyalgia syndrome in the workplace. Rheum Dis Clin North Am. 1989;15:45-60. [PMID: 2644678 DOI: 10.1074/jbc.m115.683813] [Cited by in Crossref: 86] [Cited by in F6Publishing: 55] [Article Influence: 2.6] [Reference Citation Analysis]
41 Su Q, Kumar V, Sud N, Mahato RI. MicroRNAs in the pathogenesis and treatment of progressive liver injury in NAFLD and liver fibrosis. Adv Drug Deliv Rev. 2018;129:54-63. [PMID: 29391222 DOI: 10.1016/j.addr.2018.01.009] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 12.8] [Reference Citation Analysis]
42 Hsu SH, Ghoshal K. MicroRNAs in Liver Health and Disease. Curr Pathobiol Rep 2013;1:53-62. [PMID: 23565350 DOI: 10.1007/s40139-012-0005-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
43 Mallat A, Lotersztajn S. Cellular mechanisms of tissue fibrosis. 5. Novel insights into liver fibrosis. Am J Physiol Cell Physiol 2013;305:C789-99. [PMID: 23903700 DOI: 10.1152/ajpcell.00230.2013] [Cited by in Crossref: 144] [Cited by in F6Publishing: 136] [Article Influence: 16.0] [Reference Citation Analysis]
44 Ferreira DM, Simão AL, Rodrigues CM, Castro RE. Revisiting the metabolic syndrome and paving the way for microRNAs in non-alcoholic fatty liver disease. FEBS J 2014;281:2503-24. [PMID: 24702768 DOI: 10.1111/febs.12806] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 5.1] [Reference Citation Analysis]
45 Roy S, Benz F, Luedde T, Roderburg C. The role of miRNAs in the regulation of inflammatory processes during hepatofibrogenesis. Hepatobiliary Surg Nutr 2015;4:24-33. [PMID: 25713802 DOI: 10.3978/j.issn.2304-3881.2015.01.05] [Cited by in F6Publishing: 33] [Reference Citation Analysis]
46 Schoepp M, Ströse AJ, Haier J. Dysregulation of miRNA Expression in Cancer Associated Fibroblasts (CAFs) and Its Consequences on the Tumor Microenvironment. Cancers (Basel) 2017;9:E54. [PMID: 28538690 DOI: 10.3390/cancers9060054] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 7.2] [Reference Citation Analysis]
47 Zhang K, Han Y, Hu Z, Zhang Z, Shao S, Yao Q, Zheng L, Wang J, Han X, Zhang Y, Chen T, Yao Z, Han T, Hong W. SCARNA10, a nuclear-retained long non-coding RNA, promotes liver fibrosis and serves as a potential biomarker. Theranostics 2019;9:3622-38. [PMID: 31281502 DOI: 10.7150/thno.32935] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
48 Appourchaux K, Dokmak S, Resche-Rigon M, Treton X, Lapalus M, Gattolliat CH, Porchet E, Martinot-Peignoux M, Boyer N, Vidaud M, Bedossa P, Marcellin P, Bièche I, Estrabaud E, Asselah T. MicroRNA-based diagnostic tools for advanced fibrosis and cirrhosis in patients with chronic hepatitis B and C. Sci Rep 2016;6:34935. [PMID: 27731343 DOI: 10.1038/srep34935] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
49 Gumucio J, Flood M, Harning J, Phan A, Roche S, Lynch E, Bedi A, Mendias C. T lymphocytes are not required for the development of fatty degeneration after rotator cuff tear. Bone Joint Res 2014;3:262-72. [PMID: 25185444 DOI: 10.1302/2046-3758.39.2000294] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
50 Huang J, Yu X, Fries JW, Zhang L, Odenthal M. MicroRNA function in the profibrogenic interplay upon chronic liver disease. Int J Mol Sci 2014;15:9360-71. [PMID: 24871365 DOI: 10.3390/ijms15069360] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
51 Tao L, Xue D, Shen D, Ma W, Zhang J, Wang X, Zhang W, Wu L, Pan K, Yang Y, Nwosu ZC, Dooley S, Seki E, Liu C. MicroRNA-942 mediates hepatic stellate cell activation by regulating BAMBI expression in human liver fibrosis. Arch Toxicol 2018;92:2935-46. [PMID: 30097701 DOI: 10.1007/s00204-018-2278-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
52 Gumucio JP, Korn MA, Saripalli AL, Flood MD, Phan AC, Roche SM, Lynch EB, Claflin DR, Bedi A, Mendias CL. Aging-associated exacerbation in fatty degeneration and infiltration after rotator cuff tear. J Shoulder Elbow Surg 2014;23:99-108. [PMID: 23790676 DOI: 10.1016/j.jse.2013.04.011] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 6.9] [Reference Citation Analysis]
53 Yu K, Shi G, Li N. The function of MicroRNA in hepatitis B virus-related liver diseases: from Dim to Bright. Annals of Hepatology 2015;14:450-6. [DOI: 10.1016/s1665-2681(19)31165-2] [Cited by in Crossref: 7] [Article Influence: 1.0] [Reference Citation Analysis]
54 Gelu-simeon M, Sobesky R, Haïm-boukobza S, Ostos M, Teicher E, Fontaine H, Salmon-ceron D, Meyer L, Trinchet J, Paule B, Samuel D, Lewin M, Duclos-vallée J. Do the epidemiology, physiological mechanisms and characteristics of hepatocellular carcinoma in HIV-infected patients justify specific screening policies? AIDS 2014;28:1379-91. [DOI: 10.1097/qad.0000000000000300] [Cited by in Crossref: 22] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
55 Kamdem SD, Moyou-Somo R, Brombacher F, Nono JK. Host Regulators of Liver Fibrosis During Human Schistosomiasis. Front Immunol 2018;9:2781. [PMID: 30546364 DOI: 10.3389/fimmu.2018.02781] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 8.5] [Reference Citation Analysis]
56 Eguchi A, Wree A, Feldstein AE. Biomarkers of liver cell death. J Hepatol. 2014;60:1063-1074. [PMID: 24412608 DOI: 10.1016/j.jhep.2013.12.026] [Cited by in Crossref: 109] [Cited by in F6Publishing: 105] [Article Influence: 13.6] [Reference Citation Analysis]
57 Ma L, Yang X, Wei R, Ye T, Zhou JK, Wen M, Men R, Li P, Dong B, Liu L, Fu X, Xu H, Aqeilan RI, Wei YQ, Yang L, Peng Y. MicroRNA-214 promotes hepatic stellate cell activation and liver fibrosis by suppressing Sufu expression. Cell Death Dis. 2018;9:718. [PMID: 29915227 DOI: 10.1038/s41419-018-0752-1] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 9.0] [Reference Citation Analysis]
58 Riaz F, Li D. Non-coding RNA Associated Competitive Endogenous RNA Regulatory Network: Novel Therapeutic Approach in Liver Fibrosis. Curr Gene Ther 2019;19:305-17. [PMID: 31696817 DOI: 10.2174/1566523219666191107113046] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
59 Coll M, El Taghdouini A, Perea L, Mannaerts I, Vila-Casadesús M, Blaya D, Rodrigo-Torres D, Affò S, Morales-Ibanez O, Graupera I, Lozano JJ, Najimi M, Sokal E, Lambrecht J, Ginès P, van Grunsven LA, Sancho-Bru P. Integrative miRNA and Gene Expression Profiling Analysis of Human Quiescent Hepatic Stellate Cells. Sci Rep 2015;5:11549. [PMID: 26096707 DOI: 10.1038/srep11549] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 8.6] [Reference Citation Analysis]
60 Cai X, Yu L, Chen Z, Ye F, Ren Z, Jin P. Arsenic trioxide-induced upregulation of miR-1294 suppresses tumor growth in hepatocellular carcinoma by targeting TEAD1 and PIM1. Cancer Biomark 2020;28:221-30. [PMID: 32280078 DOI: 10.3233/CBM-190490] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
61 Zhu D, Yang C, Shen P, Chen L, Chen J, Sun X, Duan L, Zhang L, Zhu J, Duan Y. rSjP40 suppresses hepatic stellate cell activation by promoting microRNA-155 expression and inhibiting STAT5 and FOXO3a expression. J Cell Mol Med 2018;22:5486-93. [PMID: 30091834 DOI: 10.1111/jcmm.13819] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
62 Wu J, Huang J, Kuang S, Chen J, Li X, Chen B, Wang J, Cheng D, Shuai X. Synergistic MicroRNA Therapy in Liver Fibrotic Rat Using MRI-Visible Nanocarrier Targeting Hepatic Stellate Cells. Adv Sci (Weinh) 2019;6:1801809. [PMID: 30886803 DOI: 10.1002/advs.201801809] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
63 Wang XW, Heegaard NH, Orum H. MicroRNAs in liver disease. Gastroenterology 2012;142:1431-43. [PMID: 22504185 DOI: 10.1053/j.gastro.2012.04.007] [Cited by in Crossref: 201] [Cited by in F6Publishing: 197] [Article Influence: 20.1] [Reference Citation Analysis]
64 Dai W, Zhao J, Tang N, Zeng X, Wu K, Ye C, Shi J, Lu C, Ning B, Zhang J. MicroRNA-155 attenuates activation of hepatic stellate cell by simultaneously preventing EMT process and ERK1 signalling pathway. Liver Int. 2015;35:1234-1243. [PMID: 25142507 DOI: 10.1111/liv.12660] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
65 Kumar V, Mahato RI. Delivery and targeting of miRNAs for treating liver fibrosis. Pharm Res 2015;32:341-61. [PMID: 25186440 DOI: 10.1007/s11095-014-1497-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
66 Soronen J, Yki-Järvinen H, Zhou Y, Sädevirta S, Sarin AP, Leivonen M, Sevastianova K, Perttilä J, Laurila PP, Sigruener A, Schmitz G, Olkkonen VM. Novel hepatic microRNAs upregulated in human nonalcoholic fatty liver disease. Physiol Rep 2016;4:e12661. [PMID: 26733244 DOI: 10.14814/phy2.12661] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 4.5] [Reference Citation Analysis]
67 Huang Y, Fan X, Tao R, Song Q, Wang L, Zhang H, Kong H, Huang J. Effect of miR-182 on hepatic fibrosis induced by Schistosomiasis japonica by targeting FOXO1 through PI3K/AKT signaling pathway. J Cell Physiol 2018;233:6693-704. [PMID: 29323718 DOI: 10.1002/jcp.26469] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
68 Wilson JA, Sagan SM. Hepatitis C virus and human miR-122: insights from the bench to the clinic. Curr Opin Virol. 2014;7:11-18. [PMID: 24721497 DOI: 10.1016/j.coviro.2014.03.005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
69 Shen W, Chen G, Dong R, Zhao R, Zheng S. MicroRNA-21/PTEN/Akt axis in the fibrogenesis of biliary atresia. Journal of Pediatric Surgery 2014;49:1738-41. [DOI: 10.1016/j.jpedsurg.2014.09.009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
70 Teng KY, Ghoshal K. Role of Noncoding RNAs as Biomarker and Therapeutic Targets for Liver Fibrosis. Gene Expr 2015;16:155-62. [PMID: 26637395 DOI: 10.3727/105221615X14399878166078] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
71 González-Fernández B, Sánchez DI, González-Gallego J, Tuñón MJ. Sphingosine 1-Phosphate Signaling as a Target in Hepatic Fibrosis Therapy. Front Pharmacol 2017;8:579. [PMID: 28890699 DOI: 10.3389/fphar.2017.00579] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
72 Li ZJ, Ou-Yang PH, Han XP. Profibrotic effect of miR-33a with Akt activation in hepatic stellate cells. Cell Signal. 2014;26:141-148. [PMID: 24100264 DOI: 10.1016/j.cellsig.2013.09.018] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 4.6] [Reference Citation Analysis]
73 Sekiba K, Otsuka M, Ohno M, Yamagami M, Kishikawa T, Suzuki T, Ishibashi R, Seimiya T, Tanaka E, Koike K. Hepatitis B virus pathogenesis: Fresh insights into hepatitis B virus RNA. World J Gastroenterol 2018; 24(21): 2261-2268 [PMID: 29881235 DOI: 10.3748/wjg.v24.i21.2261] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
74 Kawada N. Cytoglobin as a Marker of Hepatic Stellate Cell-derived Myofibroblasts. Front Physiol 2015;6:329. [PMID: 26617531 DOI: 10.3389/fphys.2015.00329] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
75 Zeng C, Wang YL, Xie C, Sang Y, Li TJ, Zhang M, Wang R, Zhang Q, Zheng L, Zhuang SM. Identification of a novel TGF-β-miR-122-fibronectin 1/serum response factor signaling cascade and its implication in hepatic fibrogenesis. Oncotarget 2015;6:12224-33. [PMID: 25909171 DOI: 10.18632/oncotarget.3652] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 6.8] [Reference Citation Analysis]
76 Panic A, Stanimirovic J, Obradovic M, Sudar-Milovanovic E, Perovic M, Lackovic M, Petrovic N, Isenovic ER. Estradiol-mediated regulation of hepatic iNOS in obese rats: Impact of Src, ERK1/2, AMPKα, and miR-221. Biotechnol Appl Biochem 2018;65:797-806. [PMID: 29957877 DOI: 10.1002/bab.1680] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
77 Sodum N, Kumar G, Bojja SL, Kumar N, Rao CM. Epigenetics in NAFLD/NASH: Targets and therapy. Pharmacol Res 2021;167:105484. [PMID: 33771699 DOI: 10.1016/j.phrs.2021.105484] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
78 Yu F, Guo Y, Chen B, Dong P, Zheng J. MicroRNA-17-5p activates hepatic stellate cells through targeting of Smad7. Lab Invest. 2015;95:781-789. [PMID: 25915722 DOI: 10.1038/labinvest.2015.58] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 6.9] [Reference Citation Analysis]
79 Zhao JW, Wang YG, Shi M. Role of extracellular vesicles in diagnosis and treatment of liver fibrosis. Shijie Huaren Xiaohua Zazhi 2019; 27(8): 515-520 [DOI: 10.11569/wcjd.v27.i8.515] [Reference Citation Analysis]
80 Yu Y, Zhu J, Liu J, Huang M, Wan JX. Identification of 8-miRNAs as biomarkers for nonalcoholic fatty liver disease. J Cell Physiol 2019;234:17361-9. [PMID: 30790285 DOI: 10.1002/jcp.28356] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
81 Chen L, Chen R, Velazquez VM, Brigstock DR. Fibrogenic Signaling Is Suppressed in Hepatic Stellate Cells through Targeting of Connective Tissue Growth Factor (CCN2) by Cellular or Exosomal MicroRNA-199a-5p. Am J Pathol. 2016;186:2921-2933. [PMID: 27662798 DOI: 10.1016/j.ajpath.2016.07.011] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 6.3] [Reference Citation Analysis]
82 Yan C, Shen LP, Ma R, Li B, Li XY, Hua H, Zhang B, Yu Q, Wang YG, Tang RX, Zheng KY. Characterization and identification of differentially expressed microRNAs during the process of the peribiliary fibrosis induced by Clonorchis sinensis. Infect Genet Evol 2016;43:321-8. [PMID: 27267304 DOI: 10.1016/j.meegid.2016.06.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
83 Sun S, Wang H, Ji M. Overexpression of miR-222-3p Promotes the Proliferation and Inhibits the Apoptosis of Diffuse Large B-Cell Lymphoma Cells via Suppressing PPP2R2A. Technol Cancer Res Treat 2019;18:1533033819892256. [PMID: 31829105 DOI: 10.1177/1533033819892256] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
84 Atta HM. Reversibility and heritability of liver fibrosis: Implications for research and therapy. World J Gastroenterol 2015; 21(17): 5138-5148 [PMID: 25954087 DOI: 10.3748/wjg.v21.i17.5138] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 33] [Article Influence: 4.3] [Reference Citation Analysis]
85 Chistiakov DA, Sobenin IA, Orekhov AN, Bobryshev YV. Human miR-221/222 in Physiological and Atherosclerotic Vascular Remodeling. Biomed Res Int. 2015;2015:354517. [PMID: 26221589 DOI: 10.1155/2015/354517] [Cited by in Crossref: 83] [Cited by in F6Publishing: 84] [Article Influence: 11.9] [Reference Citation Analysis]
86 Morishita A, Yoneyama H, Iwama H, Fujita K, Watanabe M, Hirose K, Tadokoro T, Oura K, Sakamoto T, Mimura S, Nomura T, Oryu M, Himoto T, Shimotohno K, Masaki T. Circulating microRNA-636 is associated with the elimination of hepatitis C virus by ombitasvir/paritaprevir/ritonavir. Oncotarget 2018;9:32054-62. [PMID: 30174796 DOI: 10.18632/oncotarget.25889] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
87 Thibault PA, Wilson JA. Targeting miRNAs to treat Hepatitis C Virus infections and liver pathology: Inhibiting the virus and altering the host. Pharmacol Res 2013;75:48-59. [PMID: 23541631 DOI: 10.1016/j.phrs.2013.03.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
88 Tumurbaatar B, Tikhanovich I, Li Z, Ren J, Ralston R, Kuravi S, Campbell R, Chaturvedi G, Huang TT, Zhao J. Hepatitis C and alcohol exacerbate liver injury by suppression of FOXO3. Am J Pathol. 2013;183:1803-1814. [PMID: 24225087 DOI: 10.1016/j.ajpath.2013.08.013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
89 Puche JE, Saiman Y, Friedman SL. Hepatic stellate cells and liver fibrosis. Compr Physiol. 2013;3:1473-1492. [PMID: 24265236 DOI: 10.1002/cphy.c120035] [Cited by in Crossref: 347] [Cited by in F6Publishing: 346] [Article Influence: 43.4] [Reference Citation Analysis]
90 Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, Shen R, Huang Y, Chen HC, Lee CH, Tsai TF, Hsu MT, Wu JC, Huang HD, Shiao MS, Hsiao M, Tsou AP. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 2012;122:2884-97. [PMID: 22820290 DOI: 10.1172/JCI63455] [Cited by in Crossref: 562] [Cited by in F6Publishing: 348] [Article Influence: 56.2] [Reference Citation Analysis]
91 Gori M, Arciello M, Balsano C. MicroRNAs in nonalcoholic fatty liver disease: novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma. Biomed Res Int. 2014;2014:741465. [PMID: 24745023 DOI: 10.1155/2014/741465] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 5.1] [Reference Citation Analysis]
92 El-Halawany MS, Ismail HM, Zeeneldin AA, Elfiky A, Tantawy M, Kobaisi MH, Hamed I, Abdel Wahab AH. Investigating the pretreatment miRNA expression patterns of advanced hepatocellular carcinoma patients in association with response to TACE treatment. Biomed Res Int 2015;2015:649750. [PMID: 25811030 DOI: 10.1155/2015/649750] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
93 Van Keuren-Jensen KR, Malenica I, Courtright AL, Ghaffari LT, Starr AP, Metpally RP, Beecroft TA, Carlson EW, Kiefer JA, Pockros PJ. microRNA changes in liver tissue associated with fibrosis progression in patients with hepatitis C. Liver Int. 2016;36:334-343. [PMID: 26189820 DOI: 10.1111/liv.12919] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
94 Hu J, Chen C, Liu Q, Liu B, Song C, Zhu S, Wu C, Liu S, Yu H, Yao D, Kang J, Zhu L. The role of the miR-31/FIH1 pathway in TGF-β-induced liver fibrosis. Clin Sci (Lond) 2015;129:305-17. [PMID: 25728779 DOI: 10.1042/CS20140012] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 5.1] [Reference Citation Analysis]
95 Pant K, Venugopal SK. Circulating microRNAs: Possible role as non-invasive diagnostic biomarkers in liver disease. Clinics and Research in Hepatology and Gastroenterology 2017;41:370-7. [DOI: 10.1016/j.clinre.2016.11.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
96 Yu L, Zheng J, Li J, Wang Y, Lu X, Fan X. Integrating serum exosomal microRNA and liver microRNA profiles disclose the function role of autophagy and mechanisms of Fructus Meliae Toosendan-induced hepatotoxicity in mice. Biomed Pharmacother 2020;123:109709. [PMID: 31855734 DOI: 10.1016/j.biopha.2019.109709] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
97 Gallego-Durán R, Romero-Gómez M. Epigenetic mechanisms in non-alcoholic fatty liver disease: An emerging field. World J Hepatol 2015; 7(24): 2497-2502 [PMID: 26523202 DOI: 10.4254/wjh.v7.i24.2497] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
98 Ezhilarasan D. MicroRNA interplay between hepatic stellate cell quiescence and activation. Eur J Pharmacol 2020;885:173507. [PMID: 32858048 DOI: 10.1016/j.ejphar.2020.173507] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
99 Yang X, Ma L, Wei R, Ye T, Zhou J, Wen M, Men R, Aqeilan RI, Peng Y, Yang L. Twist1-induced miR-199a-3p promotes liver fibrosis by suppressing caveolin-2 and activating TGF-β pathway. Signal Transduct Target Ther 2020;5:75. [PMID: 32499481 DOI: 10.1038/s41392-020-0169-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
100 Li H, Jiang JD, Peng ZG. MicroRNA-mediated interactions between host and hepatitis C virus. World J Gastroenterol 2016; 22(4): 1487-1496 [PMID: 26819516 DOI: 10.3748/wjg.v22.i4.1487] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
101 Hung CH, Chiu YC, Chen CH, Hu TH. MicroRNAs in hepatocellular carcinoma: carcinogenesis, progression, and therapeutic target. Biomed Res Int. 2014;2014:486407. [PMID: 24800233 DOI: 10.1155/2014/486407] [Cited by in Crossref: 37] [Cited by in F6Publishing: 50] [Article Influence: 4.6] [Reference Citation Analysis]
102 Lendvai G, Szekerczés T, Gyöngyösi B, Schlachter K, Kontsek E, Pesti A, Patonai A, Werling K, Kovalszky I, Schaff Z, Kiss A. MicroRNA Expression in Focal Nodular Hyperplasia in Comparison with Cirrhosis and Hepatocellular Carcinoma. Pathol Oncol Res 2019;25:1103-9. [PMID: 30411298 DOI: 10.1007/s12253-018-0528-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
103 Dongiovanni P, Meroni M, Longo M, Fargion S, Fracanzani AL. miRNA Signature in NAFLD: A Turning Point for a Non-Invasive Diagnosis. Int J Mol Sci 2018;19:E3966. [PMID: 30544653 DOI: 10.3390/ijms19123966] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 11.5] [Reference Citation Analysis]
104 Lino Cardenas CL, Henaoui IS, Courcot E, Roderburg C, Cauffiez C, Aubert S, Copin MC, Wallaert B, Glowacki F, Dewaeles E, Milosevic J, Maurizio J, Tedrow J, Marcet B, Lo-Guidice JM, Kaminski N, Barbry P, Luedde T, Perrais M, Mari B, Pottier N. miR-199a-5p Is upregulated during fibrogenic response to tissue injury and mediates TGFbeta-induced lung fibroblast activation by targeting caveolin-1. PLoS Genet. 2013;9:e1003291. [PMID: 23459460 DOI: 10.1371/journal.pgen.1003291] [Cited by in Crossref: 153] [Cited by in F6Publishing: 146] [Article Influence: 17.0] [Reference Citation Analysis]
105 Yasser MB, Abdellatif M, Emad E, Jafer A, Ahmed S, Nageb L, Abdelshafy H, Al-Anany AM, Al-Arab MAE, Gibriel AA. Circulatory miR-221 & miR-542 expression profiles as potential molecular biomarkers in Hepatitis C Virus mediated liver cirrhosis and hepatocellular carcinoma. Virus Res 2021;296:198341. [PMID: 33607184 DOI: 10.1016/j.virusres.2021.198341] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Alipoor B, Nikouei S, Rezaeinejad F, Malakooti-Dehkordi SN, Sabati Z, Ghasemi H. Long non-coding RNAs in metabolic disorders: pathogenetic relevance and potential biomarkers and therapeutic targets. J Endocrinol Invest 2021;44:2015-41. [PMID: 33792864 DOI: 10.1007/s40618-021-01559-8] [Reference Citation Analysis]
107 Zhang Y, Luo G, Zhang Y, Zhang M, Zhou J, Gao W, Xuan X, Yang X, Yang D, Tian Z, Ni B, Tang J. Critical effects of long non-coding RNA on fibrosis diseases. Exp Mol Med 2018;50:e428. [PMID: 29350677 DOI: 10.1038/emm.2017.223] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
108 El Sayed NF, Abdallah DM, Awad AS, Ahmed KA, El-Abhar HS. Novel peripheral role of Nurr-1/GDNF/AKT trajectory in carvedilol and/or morin hydrate hepatoprotective effect in a model of hepatic ischemia/reperfusion. Life Sci 2021;273:119235. [PMID: 33607152 DOI: 10.1016/j.lfs.2021.119235] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
109 Kitano M, Bloomston PM. Hepatic Stellate Cells and microRNAs in Pathogenesis of Liver Fibrosis. J Clin Med. 2016;5. [PMID: 26999230 DOI: 10.3390/jcm5030038] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 10.3] [Reference Citation Analysis]
110 Markovic J, Sharma AD, Balakrishnan A. MicroRNA-221: A Fine Tuner and Potential Biomarker of Chronic Liver Injury. Cells 2020;9:E1767. [PMID: 32717951 DOI: 10.3390/cells9081767] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
111 Higashi M, Yoneda M, Nakagawa T, Ikeda M, Ito T. miR-222 regulates proliferation of primary mouse hepatocytes in vitro. Biochem Biophys Res Commun 2019;511:644-9. [PMID: 30826054 DOI: 10.1016/j.bbrc.2019.02.093] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
112 Tsay HC, Yuan Q, Balakrishnan A, Kaiser M, Möbus S, Kozdrowska E, Farid M, Tegtmeyer PK, Borst K, Vondran FWR, Kalinke U, Kispert A, Manns MP, Ott M, Sharma AD. Hepatocyte-specific suppression of microRNA-221-3p mitigates liver fibrosis. J Hepatol 2019;70:722-34. [PMID: 30582979 DOI: 10.1016/j.jhep.2018.12.016] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
113 Yu F, Guo Y, Chen B, Dong P, Zheng J. MicroRNA-17-5p activates hepatic stellate cells through targeting of Smad7. Lab Invest. 2015;95:781-789. [PMID: 25915722 DOI: 10.1038/labinvest. 2015.58] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
114 Bandopadhyay M, Bharadwaj M. Exosomal miRNAs in hepatitis B virus related liver disease: a new hope for biomarker. Gut Pathog. 2020;12:23. [PMID: 32346400 DOI: 10.1186/s13099-020-00353-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
115 Paulusch S, Kalthoff S, Landerer S, Jansen C, Schierwagen R, Klein S, Trebicka J, Strassburg CP. Regulation of uridine diphosphate-glucuronosyltransferase 1A expression by miRNA-214-5p and miRNA-486-3p. Epigenomics 2021;13:271-83. [PMID: 33432840 DOI: 10.2217/epi-2020-0244] [Reference Citation Analysis]
116 Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 2017;14:397-411. [PMID: 28487545 DOI: 10.1038/nrgastro.2017.38] [Cited by in Crossref: 770] [Cited by in F6Publishing: 749] [Article Influence: 154.0] [Reference Citation Analysis]
117 Ding CL, Xu G, Ren H, Zhao LJ, Zhao P, Qi ZT, Wang W. HCV infection induces the upregulation of miR-221 in NF-κB dependent manner. Virus Res 2015;196:135-9. [PMID: 25433287 DOI: 10.1016/j.virusres.2014.11.023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
118 Elpek G&. Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update. World J Gastroenterol 2014; 20(23): 7260-7276 [PMID: 24966597 DOI: 10.3748/wjg.v20.i23.7260] [Cited by in CrossRef: 173] [Cited by in F6Publishing: 156] [Article Influence: 21.6] [Reference Citation Analysis]
119 Sarkar N, Chakravarty R. Hepatitis B Virus Infection, MicroRNAs and Liver Disease. Int J Mol Sci. 2015;16:17746-17762. [PMID: 26247932 DOI: 10.3390/ijms160817746] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
120 Auguet T, Aragonès G, Berlanga A, Guiu-Jurado E, Martí A, Martínez S, Sabench F, Hernández M, Aguilar C, Sirvent JJ, Del Castillo D, Richart C. miR33a/miR33b* and miR122 as Possible Contributors to Hepatic Lipid Metabolism in Obese Women with Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2016;17:E1620. [PMID: 27669236 DOI: 10.3390/ijms17101620] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
121 Shaker OG, Senousy MA. Serum microRNAs as predictors for liver fibrosis staging in hepatitis C virus-associated chronic liver disease patients. J Viral Hepat. 2017;24:636-644. [PMID: 28211229 DOI: 10.1111/jvh.12696] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
122 Huan L, Liang LH, He XH. Role of microRNAs in inflammation-associated liver cancer. Cancer Biol Med 2016;13:407-25. [PMID: 28154773 DOI: 10.20892/j.issn.2095-3941.2016.0071] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
123 Yang J, Zhang JY, Chen J, Xu Y, Song NH, Yin CJ. Prognostic role of microRNA-221 in various human malignant neoplasms: a meta-analysis of 20 related studies. PLoS One 2014;9:e87606. [PMID: 24475314 DOI: 10.1371/journal.pone.0087606] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
124 Su TH, Kao JH, Liu CJ. Molecular mechanism and treatment of viral hepatitis-related liver fibrosis. Int J Mol Sci. 2014;15:10578-10604. [PMID: 24927147 DOI: 10.3390/ijms150610578] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 5.5] [Reference Citation Analysis]
125 Wei YF, Cui GY, Ye P, Chen JN, Diao HY. MicroRNAs may solve the mystery of chronic hepatitis B virus infection. World J Gastroenterol 2013; 19(30): 4867-4876 [PMID: 23946591 DOI: 10.3748/wjg.v19.i30.4867] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
126 Hintikka J, Lensu S, Mäkinen E, Karvinen S, Honkanen M, Lindén J, Garrels T, Pekkala S, Lahti L. Xylo-Oligosaccharides in Prevention of Hepatic Steatosis and Adipose Tissue Inflammation: Associating Taxonomic and Metabolomic Patterns in Fecal Microbiomes with Biclustering. Int J Environ Res Public Health 2021;18:4049. [PMID: 33921370 DOI: 10.3390/ijerph18084049] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 Lin HY, Yang YL, Wang PW, Wang FS, Huang YH. The Emerging Role of MicroRNAs in NAFLD: Highlight of MicroRNA-29a in Modulating Oxidative Stress, Inflammation, and Beyond. Cells 2020;9:E1041. [PMID: 32331364 DOI: 10.3390/cells9041041] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
128 Sulaiman SA, Muhsin NIA, Jamal R. Regulatory Non-coding RNAs Network in Non-alcoholic Fatty Liver Disease. Front Physiol 2019;10:279. [PMID: 30941061 DOI: 10.3389/fphys.2019.00279] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
129 Kim KM, Kim SG. Autophagy and microRNA dysregulation in liver diseases. Arch Pharm Res 2014;37:1097-116. [PMID: 25015129 DOI: 10.1007/s12272-014-0439-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
130 Yang X, Dan X, Men R, Ma L, Wen M, Peng Y, Yang L. MiR-142-3p blocks TGF-β-induced activation of hepatic stellate cells through targeting TGFβRI. Life Sciences 2017;187:22-30. [DOI: 10.1016/j.lfs.2017.08.017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
131 Yu J, Zhang W, Qian H, Tang H, Lin W, Lu B. SOCS1 regulates hepatic regenerative response and provides prognostic makers for acute obstructive cholangitis. Sci Rep 2017;7:9482. [PMID: 28842621 DOI: 10.1038/s41598-017-09865-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
132 Zhou WC, Zhang QB, Qiao L. Pathogenesis of liver cirrhosis. World J Gastroenterol 2014; 20(23): 7312-7324 [PMID: 24966602 DOI: 10.3748/wjg.v20.i23.7312] [Cited by in CrossRef: 202] [Cited by in F6Publishing: 178] [Article Influence: 25.3] [Reference Citation Analysis]
133 Murakami Y, Kawada N. MicroRNAs in hepatic pathophysiology. Hepatol Res. 2017;47:60-69. [PMID: 27101519 DOI: 10.1111/hepr.12730] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 5.8] [Reference Citation Analysis]
134 Zheng J, Dong P, Mao Y, Chen S, Wu X, Li G, Lu Z, Yu F. lincRNA-p21 inhibits hepatic stellate cell activation and liver fibrogenesis via p21. FEBS J 2015;282:4810-21. [DOI: 10.1111/febs.13544] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
135 Vickers KC, Landstreet SR, Levin MG, Shoucri BM, Toth CL, Taylor RC, Palmisano BT, Tabet F, Cui HL, Rye KA, Sethupathy P, Remaley AT. MicroRNA-223 coordinates cholesterol homeostasis. Proc Natl Acad Sci U S A 2014;111:14518-23. [PMID: 25246565 DOI: 10.1073/pnas.1215767111] [Cited by in Crossref: 155] [Cited by in F6Publishing: 151] [Article Influence: 19.4] [Reference Citation Analysis]
136 Huang D, Chen Z, Wang J, Chen Y, Liu D, Lin K. MicroRNA-221 is a potential biomarker of myocardial hypertrophy and fibrosis in hypertrophic obstructive cardiomyopathy. Biosci Rep 2020;40:BSR20191234. [PMID: 31868204 DOI: 10.1042/BSR20191234] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
137 Niu X, Nong S, Gong J, Zhang X, Tang H, Zhou T, Li W. Research on promoting liver fibrosis injury by the targeted regulation of miR-202 for HGF to activate HSC. Ir J Med Sci 2020;189:1295-304. [PMID: 32270431 DOI: 10.1007/s11845-020-02210-w] [Reference Citation Analysis]
138 Huang CF, Sun CC, Zhao F, Zhang YD, Li DJ. miR-33a levels in hepatic and serum after chronic HBV-induced fibrosis. J Gastroenterol. 2015;50:480-490. [PMID: 25155445 DOI: 10.1007/s00535-014-0986-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
139 Ren L, Yang C, Dou Y, Zhan R, Sun Y, Yu Y. MiR-541-5p regulates lung fibrosis by targeting cyclic nucleotide phosphodiesterase 1A. Exp Lung Res 2017;43:249-58. [PMID: 28816543 DOI: 10.1080/01902148.2017.1349210] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
140 Messner CJ, Schmidt S, Özkul D, Gaiser C, Terracciano L, Krähenbühl S, Suter-Dick L. Identification of miR-199a-5p, miR-214-3p and miR-99b-5p as Fibrosis-Specific Extracellular Biomarkers and Promoters of HSC Activation. Int J Mol Sci 2021;22:9799. [PMID: 34575957 DOI: 10.3390/ijms22189799] [Reference Citation Analysis]
141 Gu S, Chan WY. Flexible and versatile as a chameleon-sophisticated functions of microRNA-199a. Int J Mol Sci 2012;13:8449-66. [PMID: 22942713 DOI: 10.3390/ijms13078449] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 4.1] [Reference Citation Analysis]
142 Masamune A, Nakano E, Hamada S, Takikawa T, Yoshida N, Shimosegawa T. Alteration of the microRNA expression profile during the activation of pancreatic stellate cells. Scand J Gastroenterol. 2014;49:323-331. [PMID: 24404812 DOI: 10.3109/00365521.2013.876447] [Cited by in Crossref: 30] [Cited by in F6Publishing: 59] [Article Influence: 3.8] [Reference Citation Analysis]
143 Feng X, Tan W, Cheng S, Wang H, Ye S, Yu C, He Y, Zeng J, Cen J, Hu J, Zheng R, Zhou Y. Upregulation of microRNA-126 in hepatic stellate cells may affect pathogenesis of liver fibrosis through the NF-κB pathway. DNA Cell Biol 2015;34:470-80. [PMID: 25974152 DOI: 10.1089/dna.2014.2760] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
144 Mandraffino G, Lo Gullo A, Cinquegrani M, D'Ascola A, Sinicropi D, Imbalzano E, Blando G, Campo GM, Morace C, Giuffrida C, Campo S, Squadrito G, Scuruchi M. Expression and Change of miRs 145, 221 and 222 in Hypertensive Subjects Treated with Enalapril, Losartan or Olmesartan. Biomedicines 2021;9:860. [PMID: 34440064 DOI: 10.3390/biomedicines9080860] [Reference Citation Analysis]
145 Lendvai G, Jármay K, Karácsony G, Halász T, Kovalszky I, Baghy K, Wittmann T, Schaff Z, Kiss A. Elevated miR-33a and miR-224 in steatotic chronic hepatitis C liver biopsies. World J Gastroenterol 2014; 20(41): 15343-15350 [PMID: 25386083 DOI: 10.3748/wjg.v20.i41.15343] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
146 Sabater L, Locatelli L, Oakley F, Hardy T, French J, Robinson SM, Sen G, Mann DA, Mann J. RNA sequencing reveals changes in the microRNAome of transdifferentiating hepatic stellate cells that are conserved between human and rat. Sci Rep 2020;10:21708. [PMID: 33303921 DOI: 10.1038/s41598-020-78776-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
147 Abdel-Al A, El-Ahwany E, Zoheiry M, Hassan M, Ouf A, Abu-Taleb H, Abdel Rahim A, El-Talkawy MD, Zada S. miRNA-221 and miRNA-222 are promising biomarkers for progression of liver fibrosis in HCV Egyptian patients. Virus Res 2018;253:135-9. [PMID: 29932949 DOI: 10.1016/j.virusres.2018.06.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
148 Vasconcellos R, Alvarenga ÉC, Parreira RC, Lima SS, Resende RR. Exploring the cell signalling in hepatocyte differentiation. Cellular Signalling 2016;28:1773-88. [DOI: 10.1016/j.cellsig.2016.08.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
149 Page A, Mann DA, Mann J. The mechanisms of HSC activation and epigenetic regulation of HSCs phenotypes. Curr Pathobiol Rep 2014;2:163-70. [PMID: 27413631 DOI: 10.1007/s40139-014-0052-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
150 Fan HX, Tang H. Complex interactions between microRNAs and hepatitis B/C viruses. World J Gastroenterol 2014; 20(37): 13477-13492 [PMID: 25309078 DOI: 10.3748/wjg.v20.i37.13477] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
151 Santangelo L, Bordoni V, Montaldo C, Cimini E, Zingoni A, Battistelli C, D'Offizi G, Capobianchi MR, Santoni A, Tripodi M, Agrati C. Hepatitis C virus direct-acting antivirals therapy impacts on extracellular vesicles microRNAs content and on their immunomodulating properties. Liver Int 2018;38:1741-50. [PMID: 29359389 DOI: 10.1111/liv.13700] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
152 Jiang X, Jiang L, Shan A, Su Y, Cheng Y, Song D, Ji H, Ning G, Wang W, Cao Y. Targeting hepatic miR-221/222 for therapeutic intervention of nonalcoholic steatohepatitis in mice. EBioMedicine 2018;37:307-21. [PMID: 30316865 DOI: 10.1016/j.ebiom.2018.09.051] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]